The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Endokrynologia Polska

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 20806180
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia

  2009cited by this paper
• Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study

  2009cited by this paper
• The economic costs of diabetes: a population-based study in Tehran, Iran

  2009cited by this paper
• Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study

  2009influential reference
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts

  2008cited by this paper
• Importance of observational studies in clinical practice.

  2007cited by this paper
• Measuring the Impact of Diabetes Through Patient Report of Treatment Satisfaction, Productivity and Symptom Experience

  2006cited by this paper
• Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)

  2006cited by this paper
• Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

  2005cited by this paper
• Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.

  2005cited by this paper
• Post-marketing surveillance: a UK/European perspective

  2005cited by this paper
• Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.

  2004cited by this paper
• Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.

  2002cited by this paper
• Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

  2002cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.

  1993cited by this paper
• Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes.

  1985cited by this paper

• Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

  2016cites this paper
• Diabetes Care in Iran: Where We Stand and Where We Are Headed.

  2016cites this paper
• Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis

  2015cites this paper
• Risk of severe hypoglycaemia for various treatment regimens – a systematic review and meta-analysis of observational studies

  2014cites this paper
• Insulin analogue therapy improves quality of life in patients with type 2 diabetes in India: the A1chieve study.

  2013cites this paper
• Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.

  2013cites this paper
• Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen

  2013cites this paper
• Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naïve Patients with Type 2 Diabetes

  2012cites this paper
• Ten Years of Experience with Biphasic Insulin Aspart 30

  2012cites this paper
• Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study.

  2011cites this paper